心臓マーカー検査市場規模、シェア、動向、2031年までの世界予測

心臓マーカー検査市場は、2025年には約50億7,000万米ドル、2026年には55億4,000万米ドルと評価され、2031年には90億6,000万米ドルに成長し、成長率は10.3%に達するとMarketsandMarketsでは予測しています。市場は着実に成長しており、病院や検査機関は、疾患の早期発見と正確な診断、そして患者の予後改善に注力しています。心血管疾患の複雑化、そして政府機関による正確な診断結果と品質管理の必要性も、心臓マーカー検査ソリューションに対する世界的な需要を牽引しています。

調査範囲：

本調査レポートは、心臓マーカー検査市場を、製品（試薬・キット、機器）、技術（免疫測定法、臨床化学）、適応症（心筋梗塞、うっ血性心不全、急性冠症候群、動脈硬化、虚血）、バイオマーカーの種類（トロポニンI・T、クレアチンキナーゼ-MB、脳性ナトリウム利尿ペプチド、ミオグロビン、高感度C反応性タンパク質、ホモシステイン、その他の心臓バイオマーカー）、検査ポイント（臨床検査、ポイントオブケア検査）、アッセイ形式（シングルプレックスアッセイ、マルチプレックスアッセイ）、エンドユーザー（臨床検査施設、学術機関、ポイントオブケア検査）、および地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）別に分類しています。本レポートは、心臓マーカー検査市場の成長に影響を与える主要な要因（推進要因、阻害要因、機会、課題など）に関する詳細な情報を網羅しています。主要企業の詳細な分析を行い、事業概要、ソリューション、パートナーシップ、コラボレーション、事業拡大、契約、製品発売などの主要戦略、および心臓マーカー検査市場における最近の動向に関する洞察を提供します。また、心臓マーカー検査市場のエコシステムにおける新興スタートアップ企業の競合分析も行います。

本レポートを購入する理由：

本レポートは、市場リーダーおよび新規参入企業に対し、心臓マーカー検査市場全体およびそのサブセグメントにおける収益の概算値に関する情報を提供します。関係者は、本レポートを通じて競争環境を理解し、より深い洞察を得て、自社の事業をより適切に位置づけ、適切な市場参入戦略を策定することができます。さらに、本レポートは、関係者が市場の動向を把握し、主要な市場推進要因、阻害要因、機会、課題に関する情報を得るのに役立ちます。

本レポートは、以下の点について洞察を提供します。

心臓マーカー検査市場の成長に影響を与える主要な推進要因（心血管疾患の罹患率の上昇、高齢者人口の増加とそれに伴う世界的な心疾患の増加、新規心臓バイオマーカーの特定に向けた臨床研究の増加、PoC検査への需要の高まり）、阻害要因（検体採取と保管に関する技術的問題、不利な規制プロセス、限られた償還制度）、機会（心血管疾患に対する新規心臓バイオマーカーに関する継続的な研究、新興市場）、および課題（バイオマーカーアッセイの検証に関連する課題）の分析。

• 製品開発／イノベーション：心臓マーカー検査市場における今後の技術、研究開発活動、および新製品の発売に関する詳細な洞察。
• 市場開発：有望な市場に関する包括的な情報 ― 本レポートは、様々な地域における心臓マーカー検査市場を分析します。
• 市場の多様化：心臓マーカー検査市場における新製品、未開拓地域、最新動向、投資に関する包括的な情報。
• 競合分析：F.Hoffmann-La Roche AG（スイス）、Abbott Laboratories（米国）、Siemens Healthineers AG（ドイツ）、Danaher Corporation（米国）といった主要企業の市場シェア、成長戦略、製品ラインナップに関する詳細な分析。

Report Description

The market for cardiac marker testing is valued at around USD 5.07 billion in 2025, USD 5.54 billion in 2026, and is forecast to reach USD 9.06 billion by 2031, representing a growth of 10.3%. The market is growing steadily, and the focus of hospitals and diagnostic laboratories is on early detection and accurate diagnosis of diseases, as well as on improving patient outcomes. The increasing complexity of cardiovascular diseases and the need for accurate diagnostic results and quality control by government agencies are also driving global demand for cardiac marker testing solutions.

“The reagents & kits segment is predicted to showcase the highest CAGR during the forecast period.”

The segment’s growth is mainly driven by recurring demand for cardiac marker kits & reagents, which are required for every test. The prevalence rate for cardiovascular diseases is also on the rise, resulting in an increased hospitalization rate for such diseases. This, in turn, is fueling the demand for cardiac marker testing kits & reagents.

“The immunoassay segment is projected to hold the largest share of the cardiac marker testing market in 2026, by technology.”

The immunoassay segment leads the market because hospital labs, reference labs, and academic institutions have adopted immunoassay-based testing, which offers higher sensitivity, specificity, and reliability for detecting cardiac biomarkers. It is the most preferred technology among healthcare providers for routine cardiac testing because immunoassay-based tests enable quick, accurate detection of myocardial infarction and related conditions. The consistent demand for immunoassay technology can be attributed to the rising incidence of cardiovascular diseases and the emphasis on early detection and management.

“Asia Pacific is expected to register the fastest growth rate in the cardiac marker testing market, by region.”

The region is witnessing a growth spurt due to several key factors, including increased healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cases of cardiovascular disease, increasing numbers of procedures performed, and growth in diagnostic labs and pharmaceutical companies are also driving growth in the cardiac marker testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the cardiac marker testing market:

• By Company Type: Tier 1 – 26%, Tier 2 – 44%, and Tier – 30%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Biomerieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Diasorin SPA (Italy), Revvity (US), Tosho Corporation (Japan), and Quidel Corporation (US).

Research Coverage:

This research report categorizes the cardiac marker testing market by product (Reagents & Kits, Instruments), technology (Immunoassay, Clinical Chemistry), indication (Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), biomarker type (Troponin I & T, Creatinine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Homocysteine, Other Cardiac Biomarkers), point of testing (Lab Test, PoC Test), assay format (Singleplex Assay, Multiplex Assay), end user (Laboratory Testing Facilities, Academic Institutes, Point-of-Care Testing), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the cardiac marker testing market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the cardiac marker testing market. This report provides a competitive analysis of emerging startups in the cardiac marker testing market ecosystem.

Reasons to buy this report:

The report will help market leaders and new entrants with information on the closest approximations of revenue numbers for the overall cardiac marker testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of cardiovascular diseases, increasing geriatric population and subsequent rise in heart conditions worldwide, rising clinical studies for identification of novel cardiac biomarkers, growing demand for PoC testing), restraints (technical issues related to sample collection and storage, unfavorable regulatory processes and limited reimbursement structure), opportunities (ongoing research on novel cardiac biomarkers for cardiovascular diseases, emerging markets), and challenges (challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the cardiac marker testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyzes the cardiac marker testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).

Table of Contents

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 39
2 EXECUTIVE SUMMARY 40
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 40
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS & STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 42
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 43
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 CARDIAC MARKER TESTING MARKET OVERVIEW 45
3.2 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2026 VS. 2031 45
3.3 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031 46
3.4 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2026 VS. 2031 46
3.5 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2026 VS. 2031 47
3.6 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2026 VS. 2031 47
3.7 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2026 VS. 2031 48
3.8 CARDIAC MARKER TESTING MARKET, BY END USER, 2026 VS. 2031 48
3.9 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
4 MARKET OVERVIEW 50
4.1 INTRODUCTION 50
4.2 MARKET DYNAMICS 50
4.2.1 DRIVERS 51
4.2.1.1 Rising prevalence of cardiovascular diseases 51
4.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 51
4.2.1.3 Rising clinical studies for identification of novel cardiac biomarkers 52
4.2.1.4 Growing demand for PoC testing 52

4.2.2 RESTRAINTS 53
4.2.2.1 Technical issues related to sample collection and storage 53
4.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 53
4.2.3 OPPORTUNITIES 54
4.2.3.1 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 54
4.2.3.2 Emerging markets 54
4.2.4 CHALLENGES 55
4.2.4.1 Challenges associated with biomarker assay validation 55
4.3 UNMET NEEDS & WHITE SPACES 55
4.3.1 UNMET NEEDS IN CARDIAC MARKER TESTING MARKET 55
4.3.2 WHITE SPACE OPPORTUNITIES 56
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 56
4.4.1 INTERCONNECTED MARKETS 56
4.4.2 CROSS-SECTOR OPPORTUNITIES 57
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 58
4.5.1 KEY MOVES & STRATEGIC FOCUS 58
5 INDUSTRY TRENDS 59
5.1 PORTER’S FIVE FORCES ANALYSIS 59
5.1.1 THREAT OF NEW ENTRANTS 60
5.1.2 THREAT OF SUBSTITUTES 60
5.1.3 BARGAINING POWER OF BUYERS 61
5.1.4 BARGAINING POWER OF SUPPLIERS 61
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.2 MACROECONOMIC INDICATORS 61
5.2.1 INTRODUCTION 61
5.2.2 GDP TRENDS & FORECAST 62
5.3 SUPPLY CHAIN ANALYSIS 64
5.4 VALUE CHAIN ANALYSIS 65
5.5 ECOSYSTEM ANALYSIS 67
5.6 PRICING ANALYSIS 68
5.6.1 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS,
BY TYPE, 2024–2026 68
5.6.2 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS,
BY KEY PLAYER, 2024–2026 69
5.6.3 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS,
BY REGION, 2024–2026 69
5.7 TRADE ANALYSIS 70
5.7.1 IMPORT SCENARIO (HS CODE 3822) 70
5.7.2 EXPORT SCENARIO (HS CODE 3822) 71
5.8 KEY CONFERENCES & EVENTS, 2026–2027 71
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
5.10 INVESTMENT & FUNDING SCENARIO 73
5.11 CASE STUDY ANALYSIS 74
5.11.1 CASE STUDY 1: IMPLEMENTATION OF HIGH-SENSITIVITY TROPONIN (HS-CTN) ASSAYS FOR RAPID MYOCARDIAL INFARCTION DIAGNOSIS 74
5.11.2 CASE STUDY 2: USE OF BNP/NT-PROBNP TESTING FOR HEART FAILURE DIAGNOSIS AND MANAGEMENT 74
5.11.3 CASE STUDY 3: USE OF HIGH-SENSITIVITY TROPONIN FOR LONG-TERM CARDIOVASCULAR RISK PREDICTION IN GENERAL POPULATION 75
5.12 IMPACT OF 2025 US TARIFFS ON CARDIAC MARKER TESTING MARKET 75
5.12.1 INTRODUCTION 75
5.12.2 KEY TARIFF RATES 76
5.12.3 PRICE IMPACT ANALYSIS 76
5.12.4 IMPACT ON REGION 77
5.12.4.1 North America 77
5.12.4.2 Europe 77
5.12.4.3 Asia Pacific 77
5.12.5 IMPACT ON END-USE INDUSTRIES 78
5.12.5.1 Hospital laboratories 78
5.12.5.2 Reference laboratories 78
5.12.5.3 Contract testing laboratories 78
5.12.5.4 Academic institutes 78
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 79
6.1 KEY EMERGING TECHNOLOGIES 79
6.1.1 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) 79
6.1.2 IMMUNOFLUORESCENCE ASSAYS (IFA) 79
6.1.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 80
6.1.4 LATERAL FLOW ASSAYS 80
6.2 COMPLEMENTARY TECHNOLOGIES 80
6.2.1 POC IMMUNOANALYZERS 80
6.2.2 DIGITAL IMMUNOASSAY PLATFORMS 80
6.3 TECHNOLOGY/PRODUCT ROADMAP 81
6.4 PATENT ANALYSIS 82
6.4.1 LIST OF MAJOR PATENTS 83
6.4.2 LIST OF KEY PATENTS 83
6.5 FUTURE APPLICATIONS 84
6.6 IMPACT OF AI/GENERATIVE AI ON CARDIAC MARKER TESTING MARKET 84
6.6.1 INTRODUCTION 84
6.6.2 TOP USE CASES & MARKET POTENTIAL 85
6.6.3 KEY COMPANIES IMPLEMENTING AI 86
6.6.4 FUTURE OF AI 86
7 SUSTAINABILITY & REGULATORY LANDSCAPE 87
7.1 REGIONAL REGULATIONS & COMPLIANCE 87
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
7.2 SUSTAINABILITY INITIATIVES 89
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CARDIAC MARKER TESTING PRODUCTS 89
7.2.1.1 Eco-friendly Initiatives 89
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 90
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91
8.1 DECISION-MAKING PROCESS 91
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 91
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
8.2.2 BUYING CRITERIA 92
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 92
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 94
8.5 MARKET PROFITABILITY 95
8.5.1 REVENUE POTENTIAL 95
8.5.2 COST DYNAMICS 95
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 96
9 CARDIAC MARKER TESTING MARKET, BY PRODUCT 97
9.1 INTRODUCTION 98
9.2 REAGENTS & KITS 98
9.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND FOR REAGENTS & KITS 98
9.3 INSTRUMENTS 101
9.3.1 EXPANDING DIAGNOSTIC INFRASTRUCTURE TO DRIVE MARKET GROWTH 101
10 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY 105
10.1 INTRODUCTION 106
10.2 IMMUN0ASSAYS 106
10.2.1 CHEMILUMINESCENCE 109
10.2.1.1 High sensitivity, wide linear range, and good specificity to aid market growth 109
10.2.2 IMMUNOFLUORESCENCE 112
10.2.2.1 Advancements in fluorescence technologies to drive immunofluorescence adoption 112
10.2.3 LATERAL FLOW IMMUNOASSAYS 114
10.2.3.1 Increasing use in point-of-care settings to propel adoption 114

10.2.4 ELISA 117
10.2.4.1 Long shelf life and ease of use to propel growth 117
10.3 CLINICAL CHEMISTRY 119
10.3.1 COST-EFFECTIVENESS AND HIGH-THROUGHPUT TESTING TO SUSTAIN GROWTH IN CLINICAL CHEMISTRY MARKET 119
11 CARDIAC MARKER TESTING MARKET, BY INDICATION 123
11.1 INTRODUCTION 124
11.2 MYOCARDIAL INFARCTION 124
11.2.1 RISING MYOCARDIAL INFARCTION BURDEN AND NEED FOR EARLY DIAGNOSIS TO DRIVE CARDIAC MARKER TESTING DEMAND 124
11.3 CONGESTIVE HEART FAILURE 126
11.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH 126
11.4 ACUTE CORONARY SYNDROME 129
11.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 129
11.5 ATHEROSCLEROSIS 131
11.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 131
11.6 ISCHEMIA 134
11.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS 134
12 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 138
12.1 INTRODUCTION 139
12.2 TROPONIN I & T 139
12.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 139
12.3 CREATININE KINASE-MB 142
12.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH 142
12.4 BRAIN NATRIURETIC PEPTIDE 144
12.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 144
12.5 MYOGLOBIN 147
12.5.1 GROWING USE TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS TO BOOST GROWTH 147
12.6 HOMOCYSTEINE 150
12.6.1 RISK STRATIFICATION AND LONG-TERM CARDIOVASCULAR RISK ASSESSMENT TO DRIVE MARKET GROWTH 150
12.7 HIGH-SENSITIVITY C-REACTIVE PROTEIN 153
12.7.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION 153
12.8 OTHER CARDIAC BIOMARKERS 155

13 CARDIAC MARKER TESTING MARKET VOLUME ANALYSIS,
BY BIOMARKER TYPE (NUMBER OF TESTS) 159
14 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING 165
14.1 INTRODUCTION 166
14.2 LAB TESTS 166
14.2.1 HIGH-SENSITIVITY, AUTOMATION, AND FLEXIBLE PROCUREMENT MODELS TO DRIVE LAB-BASED TESTING DOMINANCE 166
14.3 POC TESTS 169
14.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE SERVICES TO DRIVE MARKET 169
15 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT 172
15.1 INTRODUCTION 173
15.2 SINGLEPLEX ASSAYS 173
15.2.1 HIGH ACCURACY AND OPERATIONAL SIMPLICITY TO SUSTAIN SINGLEPLEX ASSAY DOMINANCE 173
15.3 MULTIPLEX ASSAYS 175
15.3.1 COMPREHENSIVE MULTI-BIOMARKER DETECTION AND RAPID DIAGNOSIS TO DRIVE MULTIPLEX ASSAY GROWTH 175
16 CARDIAC MARKER TESTING MARKET, BY END USER 179
16.1 INTRODUCTION 180
16.2 LABORATORY TESTING FACILITIES 180
16.2.1 HOSPITAL LABORATORIES 183
16.2.1.1 Growing focus on healthcare system to stimulate growth 183
16.2.2 REFERENCE LABORATORIES 186
16.2.2.1 Rising outsourcing and advanced testing capabilities to position reference laboratories as key growth drivers 186
16.2.3 CONTRACT TESTING LABORATORIES 189
16.2.3.1 Outsourced expertise and scalable testing capabilities to boost role of contract laboratories 189
16.3 ACADEMIC INSTITUTES 191
16.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 191
16.4 POINT-OF-CARE TESTING 194
16.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO BOOST MARKET 194
17 CARDIAC MARKER TESTING MARKET, BY REGION 197
17.1 INTRODUCTION 198
17.2 NORTH AMERICA 199
17.2.1 US 203
17.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 203
17.2.2 CANADA 207
17.2.2.1 Government initiatives to support market growth 207
17.3 EUROPE 211
17.3.1 GERMANY 215
17.3.1.1 Stringent regulations for food, pharmaceutical, and medical device industries to fuel growth 215
17.3.2 UK 219
17.3.2.1 Increasing cardiovascular patient volume to spur growth 219
17.3.3 FRANCE 222
17.3.3.1 Highly advanced and well-established healthcare system to drive demand for market 222
17.3.4 ITALY 226
17.3.4.1 Growing geriatric population and improved life expectancy to support market growth 226
17.3.5 SPAIN 230
17.3.5.1 Government efforts to improve health infrastructure to fuel demand 230
17.3.6 REST OF EUROPE 234
17.4 ASIA PACIFIC 238
17.4.1 JAPAN 243
17.4.1.1 Growing geriatric population and increasing incidence of chronic diseases to drive market 243
17.4.2 CHINA 247
17.4.2.1 Rising number of hospitals and increasing healthcare expenditure to boost adoption 247
17.4.3 INDIA 251
17.4.3.1 Infrastructural improvements to support growth 251
17.4.4 AUSTRALIA 255
17.4.4.1 Higher government healthcare expenditure to support market growth 255
17.4.5 SOUTH KOREA 258
17.4.5.1 Country’s fast-aging demographic to drive market 258
17.4.6 REST OF ASIA PACIFIC 262
17.5 LATIN AMERICA 265
17.5.1 BRAZIL 269
17.5.1.1 Rising government support to boost adoption of market 269
17.5.2 MEXICO 273
17.5.2.1 Rising geriatric population to support market growth 273
17.5.3 REST OF LATIN AMERICA 277
17.6 MIDDLE EAST & AFRICA 280

18 COMPETITIVE LANDSCAPE 285
18.1 INTRODUCTION 285
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 285
18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CARDIAC MARKER TESTING MARKET 285
18.3 REVENUE ANALYSIS, 2023–2025 287
18.4 MARKET SHARE ANALYSIS, 2025 288
18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 288
18.4.2 US MARKET SHARE ANALYSIS, 2025 290
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 290
18.5.1 STARS 290
18.5.2 EMERGING LEADERS 290
18.5.3 PERVASIVE PLAYERS 291
18.5.4 PARTICIPANTS 291
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 292
18.5.5.1 Company footprint 292
18.5.5.2 Region footprint 292
18.5.5.3 Product footprint 293
18.5.5.4 Technology footprint 293
18.5.5.5 Point of testing footprint 294
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 294
18.6.1 PROGRESSIVE COMPANIES 294
18.6.2 RESPONSIVE COMPANIES 294
18.6.3 DYNAMIC COMPANIES 294
18.6.4 STARTING BLOCKS 295
18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 296
18.6.5.1 Detailed list of key startups/SMEs 296
18.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 296
18.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 297
18.7 COMPANY VALUATION & FINANCIAL METRICS 297
18.7.1 FINANCIAL METRICS 297
18.7.2 COMPANY VALUATION 298
18.8 BRAND/PRODUCT COMPARISON 299
18.9 COMPETITIVE SCENARIO 300
18.9.1 PRODUCT APPROVALS 300
18.9.2 DEALS 300

19 COMPANY PROFILES 302
19.1 KEY PLAYERS 302
19.1.1 F. HOFFMANN-LA ROCHE AG 302
19.1.1.1 Business overview 302
19.1.1.2 Products offered 303
19.1.1.3 Recent developments 305
19.1.1.3.1 Product approvals 305
19.1.1.3.2 Deals 305
19.1.1.4 MnM view 305
19.1.1.4.1 Key strengths 305
19.1.1.4.2 Strategic choices 306
19.1.1.4.3 Weaknesses & competitive threats 306
19.1.2 ABBOTT LABORATORIES 307
19.1.2.1 Business overview 307
19.1.2.2 Products offered 308
19.1.2.3 MnM view 309
19.1.2.3.1 Key strengths 309
19.1.2.3.2 Strategic choices 309
19.1.2.3.3 Weaknesses & competitive threats 309
19.1.3 DANAHER CORPORATION 310
19.1.3.1 Business overview 310
19.1.3.2 Products offered 311
19.1.3.3 MnM view 312
19.1.3.3.1 Key strengths 312
19.1.3.3.2 Strategic choices 312
19.1.3.3.3 Weaknesses & competitive threats 312
19.1.4 SIEMENS HEALTHINEERS AG 313
19.1.4.1 Business overview 313
19.1.4.2 Products offered 314
19.1.4.3 MnM view 315
19.1.4.3.1 Key strengths 315
19.1.4.3.2 Strategic choices 315
19.1.4.3.3 Weaknesses & competitive threats 316
19.1.5 THERMO FISHER SCIENTIFIC 317
19.1.5.1 Business overview 317
19.1.5.2 Products offered 318
19.1.5.3 MnM view 319
19.1.5.3.1 Key strengths 319
19.1.5.3.2 Strategic choices 319
19.1.5.3.3 Weaknesses & competitive threats 319

19.1.6 BIO-RAD LABORATORIES 320
19.1.6.1 Business overview 320
19.1.6.2 Products offered 321
19.1.7 BIOMÉRIEUX SA 322
19.1.7.1 Business overview 322
19.1.7.2 Products offered 323
19.1.7.3 Recent developments 324
19.1.7.3.1 Deals 324
19.1.8 BECTON, DICKINSON AND COMPANY 325
19.1.8.1 Business overview 325
19.1.8.2 Products offered 326
19.1.9 DIASORIN SPA 327
19.1.9.1 Business overview 327
19.1.9.2 Products offered 328
19.1.10 REVVITY 329
19.1.10.1 Business overview 329
19.1.10.2 Products offered 331
19.1.11 TOSOH CORPORATION 332
19.1.11.1 Business overview 332
19.1.11.2 Products offered 333
19.1.12 QUIDEL CORPORATION 335
19.1.12.1 Business overview 335
19.1.12.2 Products offered 336
19.1.12.3 Recent developments 337
19.1.12.3.1 Product approvals 337
19.1.12.3.2 Deals 337
19.2 OTHER PLAYERS 338
19.2.1 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 338
19.2.2 RANDOX LABORATORIES 339
19.2.3 GUANGZHOU WONDFO BIOTECH CO., LTD. 340
19.2.4 BODITECH MED INC. 341
19.2.5 BTNX INC. 342
19.2.6 RESPONSE BIOMEDICAL 343
19.2.7 ALFA SCIENTIFIC DESIGNS, INC. 344
19.2.8 CTK BIOTECH 345
19.2.9 CREATIVE DIAGNOSTICS 346
19.2.10 LIFESIGN LLC 347
19.2.11 DIASYS DIAGNOSTIC SYSTEMS GMBH 348
19.2.12 ATLAS MEDICAL GMBH 349
19.2.13 GETEIN BIOTECH INC. 350

20 RESEARCH METHODOLOGY 351
20.1 RESEARCH DATA 351
20.1.1 SECONDARY DATA 352
20.1.1.1 List of secondary sources 352
20.1.1.2 Key data from secondary sources 353
20.1.2 PRIMARY DATA 353
20.1.2.1 List of primary sources 354
20.1.2.2 Key data from primary sources 354
20.1.2.3 Key industry insights 356
20.1.2.4 Breakdown of primary interviews 357
20.2 MARKET SIZE ESTIMATION 357
20.2.1 TOTAL MARKET SIZE: CARDIAC MARKER TESTING MARKET 357
20.2.2 BOTTOM-UP APPROACH 357
20.2.2.1 Approach 1: Revenue estimation of key players 358
20.2.2.2 Approach 2: Study of annual reports and investor presentations 358
20.2.2.3 Approach 3: Primary interviews 358
20.2.2.4 Growth forecast 358
20.2.2.5 CAGR projections 359
20.2.3 TOP-DOWN APPROACH 359
20.3 DATA TRIANGULATION 360
20.4 RESEARCH ASSUMPTIONS 361
20.4.1 STUDY-RELATED ASSUMPTIONS 361
20.4.2 GROWTH RATE ASSUMPTIONS 362
20.5 RESEARCH LIMITATIONS 362
20.6 RISK ASSESSMENT 363
21 APPENDIX 364
21.1 DISCUSSION GUIDE 364
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 368
21.3 CUSTOMIZATION OPTIONS 370
21.4 RELATED REPORTS 370
21.5 AUTHOR DETAILS 371

LIST OF TABLES

TABLE 1 CARDIAC MARKER TESTING MARKET: IMPACT OF PORTER’S FORCES 60
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 62
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 63
TABLE 4 EUROPE: MACROECONOMIC INDICATORS 63
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 63
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 64
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 64
TABLE 8 CARDIAC MARKER TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 68
TABLE 9 AVERAGE SELLING PRICING OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024–2026 (USD) 68
TABLE 10 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 69
TABLE 11 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024–2026 (USD) 70
TABLE 12 IMPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021–2025 (USD MILLION) 70
TABLE 13 EXPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021–2025 (USD MILLION) 71
TABLE 14 CARDIAC MARKER TESTING MARKET: KEY CONFERENCES & EVENTS,
2026–2027 71
TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 76
TABLE 16 KEY PATENTS IN CARDIAC MARKER TESTING MARKET, 2022–2026 83
TABLE 17 KEY COMPANIES IMPLEMENTING AI IN CARDIAC MARKER TESTING MARKET 86
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 91
TABLE 24 KEY BUYING CRITERIA, BY END USER 92
TABLE 25 ADOPTION BARRIERS & INTERNAL CHALLENGES 93
TABLE 26 CARDIAC MARKER TESTING MARKET: UNMET NEEDS IN VARIOUS
END-USE INDUSTRIES 94
TABLE 27 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 98
TABLE 28 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING REAGENTS & KITS 99
TABLE 29 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION,
2024–2031 (USD MILLION) 99
TABLE 30 NORTH AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 100
TABLE 31 EUROPE: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 100
TABLE 32 ASIA PACIFIC: CARDIAC MARKER TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 33 LATIN AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 34 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING INSTRUMENTS 102
TABLE 35 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 102
TABLE 36 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 37 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 38 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104
TABLE 39 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 104
TABLE 40 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 106
TABLE 41 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 107
TABLE 42 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031 (USD MILLION) 107
TABLE 43 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 107
TABLE 44 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 45 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 46 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 47 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2024–2031 (USD MILLION) 110
TABLE 48 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 49 EUROPE: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE,
BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 50 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE,
BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 51 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 112
TABLE 52 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 53 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 54 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE,
BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 55 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 56 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 57 CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS,
BY REGION, 2024–2031 (USD MILLION) 115
TABLE 58 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 59 EUROPE: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 60 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 61 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 62 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 63 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 64 EUROPE: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY,
2024–2031 (USD MILLION) 118
TABLE 65 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 66 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 67 CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 69 EUROPE: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 70 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 71 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 72 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 124
TABLE 73 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 76 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 77 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 78 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 79 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE , BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 80 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 81 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 82 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 83 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 84 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 87 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 88 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 89 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 90 EUROPE: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 91 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 92 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 93 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION,
2024–2031 (USD MILLION) 135
TABLE 94 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 95 EUROPE: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA,
BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 98 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 139
TABLE 99 CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 100 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T,
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 101 EUROPE: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 102 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 104 CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 105 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 106 EUROPE: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 107 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 108 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 109 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 110 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 111 EUROPE: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 112 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 113 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 114 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 115 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 116 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 117 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 118 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 119 CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 120 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 121 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 122 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE,
BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 123 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE,
BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 124 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 125 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY
C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 126 EUROPE: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 127 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY
C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 128 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY
C-REACTIVE PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 129 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS,
BY REGION, 2024–2031 (USD MILLION) 156
TABLE 130 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 131 EUROPE: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 132 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 133 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 134 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 159
TABLE 135 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 159
TABLE 136 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 160
TABLE 137 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 160
TABLE 138 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 161
TABLE 139 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 161
TABLE 140 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 162
TABLE 141 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 162
TABLE 142 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 163
TABLE 143 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 163
TABLE 144 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 164
TABLE 145 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (MILLION UNITS) 164
TABLE 146 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 166
TABLE 147 CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY REGION,
2024–2031 (USD MILLION) 167
TABLE 148 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 149 EUROPE: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 150 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 151 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 152 CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 153 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 154 EUROPE: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 155 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 156 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 157 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 173
TABLE 158 CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 159 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 160 EUROPE: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 161 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 162 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 163 CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 164 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 165 EUROPE: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 166 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 167 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 168 CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 180
TABLE 169 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES,
BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 170 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES,
BY REGION, 2024–2031 (USD MILLION) 181
TABLE 171 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 172 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 173 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 174 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 175 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 176 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 177 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 178 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 179 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 180 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 187
TABLE 181 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 182 EUROPE: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 183 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 184 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 185 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 190
TABLE 186 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 187 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 188 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 189 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 190 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 191 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 192 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 193 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 194 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 195 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 196 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 197 EUROPE: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING,
BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 198 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 199 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 200 CARDIAC MARKER TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 201 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 202 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 200
TABLE 203 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 200
TABLE 204 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 205 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 201
TABLE 206 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 201
TABLE 207 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 202
TABLE 208 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 202
TABLE 209 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 202
TABLE 210 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 211 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 204
TABLE 212 US: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 204
TABLE 213 US: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 204
TABLE 214 US: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 205
TABLE 215 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 205
TABLE 216 US: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 206
TABLE 217 US: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 206
TABLE 218 US: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 206
TABLE 219 US: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 220 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 208
TABLE 221 CANADA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 208
TABLE 222 CANADA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 223 CANADA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 209
TABLE 224 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 209
TABLE 225 CANADA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 210
TABLE 226 CANADA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 210
TABLE 227 CANADA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 210
TABLE 228 CANADA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 229 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 211
TABLE 230 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 212
TABLE 231 EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 212
TABLE 232 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 233 EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 213
TABLE 234 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 213
TABLE 235 EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 214
TABLE 236 EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 214
TABLE 237 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 214
TABLE 238 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 239 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 216
TABLE 240 GERMANY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 216
TABLE 241 GERMANY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 242 GERMANY: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 217
TABLE 243 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 217
TABLE 244 GERMANY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 218
TABLE 245 GERMANY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 218
TABLE 246 GERMANY: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 218
TABLE 247 GERMANY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 248 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 219
TABLE 249 UK: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 220
TABLE 250 UK: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 220
TABLE 251 UK: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 220
TABLE 252 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 221
TABLE 253 UK: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 221
TABLE 254 UK: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 221
TABLE 255 UK: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 222
TABLE 256 UK: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 257 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 223
TABLE 258 FRANCE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 223
TABLE 259 FRANCE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 260 FRANCE: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 224
TABLE 261 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 224
TABLE 262 FRANCE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 225
TABLE 263 FRANCE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 225
TABLE 264 FRANCE: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 225
TABLE 265 FRANCE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 266 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 227
TABLE 267 ITALY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 227
TABLE 268 ITALY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 227
TABLE 269 ITALY: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 228
TABLE 270 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 228
TABLE 271 ITALY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 229
TABLE 272 ITALY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 229
TABLE 273 ITALY: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 229
TABLE 274 ITALY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 275 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 231
TABLE 276 SPAIN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 231
TABLE 277 SPAIN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 278 SPAIN: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 232
TABLE 279 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 232
TABLE 280 SPAIN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 233
TABLE 281 SPAIN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 233
TABLE 282 SPAIN: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 233
TABLE 283 SPAIN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 284 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 235
TABLE 285 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 235
TABLE 286 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 287 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 236
TABLE 288 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 236
TABLE 289 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 237
TABLE 290 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 237
TABLE 291 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 237
TABLE 292 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 293 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 239
TABLE 294 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 240
TABLE 295 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 240
TABLE 296 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 297 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 241
TABLE 298 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 241
TABLE 299 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 242
TABLE 300 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 242
TABLE 301 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 242
TABLE 302 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 303 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 244
TABLE 304 JAPAN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 244
TABLE 305 JAPAN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 306 JAPAN: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 245
TABLE 307 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 245
TABLE 308 JAPAN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 246
TABLE 309 JAPAN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 246
TABLE 310 JAPAN: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 311 JAPAN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 312 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 248
TABLE 313 CHINA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 248
TABLE 314 CHINA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 315 CHINA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 249
TABLE 316 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 249
TABLE 317 CHINA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 250
TABLE 318 CHINA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 250
TABLE 319 CHINA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 250
TABLE 320 CHINA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 321 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 252
TABLE 322 INDIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 252
TABLE 323 INDIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 324 INDIA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 253
TABLE 325 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 253
TABLE 326 INDIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 254
TABLE 327 INDIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 254
TABLE 328 INDIA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 329 INDIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 330 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 255
TABLE 331 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 256
TABLE 332 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 333 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 256
TABLE 334 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 257
TABLE 335 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 257
TABLE 336 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 257
TABLE 337 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 258
TABLE 338 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 339 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 259
TABLE 340 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 259
TABLE 341 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY,
BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 342 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 260
TABLE 343 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 260
TABLE 344 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 261
TABLE 345 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 261
TABLE 346 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 261
TABLE 347 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 348 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 262
TABLE 349 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 263
TABLE 350 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 351 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 263
TABLE 352 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 264
TABLE 353 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 264
TABLE 354 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 264
TABLE 355 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 265
TABLE 356 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 357 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 358 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 266
TABLE 359 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 266
TABLE 360 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 361 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 267
TABLE 362 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 268
TABLE 363 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 268
TABLE 364 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 268
TABLE 365 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 269
TABLE 366 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 367 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 270
TABLE 368 BRAZIL: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 270
TABLE 369 BRAZIL: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 370 BRAZIL: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 271
TABLE 371 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 271
TABLE 372 BRAZIL: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 272
TABLE 373 BRAZIL: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 272
TABLE 374 BRAZIL: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 272
TABLE 375 BRAZIL: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 376 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 274
TABLE 377 MEXICO: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 274
TABLE 378 MEXICO: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 379 MEXICO: CARDIAC MARKER TESTING MARKET, BY INDICATION,
2024–2031 (USD MILLION) 275
TABLE 380 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,
2024–2031 (USD MILLION) 275
TABLE 381 MEXICO: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING,
2024–2031 (USD MILLION) 276
TABLE 382 MEXICO: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT,
2024–2031 (USD MILLION) 276
TABLE 383 MEXICO: CARDIAC MARKER TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 276
TABLE 384 MEXICO: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 385 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 277
TABLE 386 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278
TABLE 387 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 388 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 278
TABLE 389 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 279
TABLE 390 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 279
TABLE 391 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 279
TABLE 392 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 280
TABLE 393 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 394 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 281
TABLE 395 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 281
TABLE 396 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 397 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024–2031 (USD MILLION) 282
TABLE 398 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024–2031 (USD MILLION) 282
TABLE 399 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024–2031 (USD MILLION) 283
TABLE 400 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024–2031 (USD MILLION) 283
TABLE 401 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 283
TABLE 402 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 403 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CARDIAC MARKER TESTING MARKET, JANUARY 2023−MARCH 2026 285
TABLE 404 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION 288
TABLE 405 CARDIAC MARKER TESTING MARKET: REGION FOOTPRINT 292
TABLE 406 CARDIAC MARKER TESTING MARKET: PRODUCT FOOTPRINT 293
TABLE 407 CARDIAC MARKER TESTING MARKET: TECHNOLOGY FOOTPRINT 293
TABLE 408 CARDIAC MARKER TESTING MARKET: POINT OF TESTING FOOTPRINT 294
TABLE 409 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 296
TABLE 410 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 296
TABLE 411 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 297
TABLE 412 CARDIAC MARKER TESTING MARKET: PRODUCT APPROVALS,
JANUARY 2023–JANUARY 2026 300
TABLE 413 CARDIAC MARKER TESTING MARKET: DEALS, JANUARY 2023–JANUARY 2026 300
TABLE 414 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 302
TABLE 415 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED 303
TABLE 416 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS,
JANUARY 2023–JANUARY 2026 305
TABLE 417 F. HOFFMANN-LA ROCHE AG: DEALS, JANUARY 2023–JANUARY 2026 305
TABLE 418 ABBOTT LABORATORIES: COMPANY OVERVIEW 307
TABLE 419 ABBOTT LABORATORIES: PRODUCTS OFFERED 308
TABLE 420 DANAHER CORPORATION: COMPANY OVERVIEW 310
TABLE 421 DANAHER CORPORATION: PRODUCTS OFFERED 311
TABLE 422 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 313
TABLE 423 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 314
TABLE 424 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 317
TABLE 425 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 318
TABLE 426 BIO-RAD LABORATORIES : COMPANY OVERVIEW 320
TABLE 427 BIO-RAD LABORATORIES : PRODUCTS OFFERED 321
TABLE 428 BIOMÉRIEUX SA : COMPANY OVERVIEW 322
TABLE 429 BIOMÉRIEUX SA : PRODUCTS OFFERED 323
TABLE 430 BIOMÉRIEUX SA: DEALS, JANUARY 2023–JANUARY 2026 324
TABLE 431 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 325
TABLE 432 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 326
TABLE 433 DIASORIN SPA: COMPANY OVERVIEW 327
TABLE 434 DIASORIN SPA: PRODUCTS OFFERED 328
TABLE 435 REVVITY: COMPANY OVERVIEW 329
TABLE 436 REVVITY: PRODUCTS OFFERED 331
TABLE 437 TOSOH CORPORATION: COMPANY OVERVIEW 332
TABLE 438 TOSOH CORPORATION: PRODUCTS OFFERED 333
TABLE 439 QUIDEL CORPORATION: COMPANY OVERVIEW 335
TABLE 440 QUIDEL CORPORATION: PRODUCTS OFFERED 336
TABLE 441 QUIDEL CORPORATION: PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 337
TABLE 442 QUIDEL CORPORATION: DEALS, JANUARY 2023–JANUARY 2026 337
TABLE 443 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION):
COMPANY OVERVIEW 338
TABLE 444 RANDOX LABORATORIES: COMPANY OVERVIEW 339
TABLE 445 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW 340
TABLE 446 BODITECH MED INC.: COMPANY OVERVIEW 341
TABLE 447 BTNX INC.: COMPANY OVERVIEW 342
TABLE 448 RESPONSE BIOMEDICAL: COMPANY OVERVIEW 343
TABLE 449 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW 344
TABLE 450 CTK BIOTECH: COMPANY OVERVIEW 345
TABLE 451 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 346
TABLE 452 LIFESIGN LLC: COMPANY OVERVIEW 347
TABLE 453 DIASYS DIAGNOSTIC SYSTEMS GMBH: COMPANY OVERVIEW 348
TABLE 454 ATLAS MEDICAL GMBH: COMPANY OVERVIEW 349
TABLE 455 GETEIN BIOTECH INC.: COMPANY OVERVIEW 350
TABLE 456 STUDY ASSUMPTIONS 361
TABLE 457 CARDIAC MARKER TESTING MARKET: RISK ASSESSMENT 363

LIST OF FIGURES

FIGURE 1 CARDIAC MARKER TESTING MARKET SEGMENTATION & REGIONAL SCOPE 36
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 40
FIGURE 3 GLOBAL CARDIAC MARKER TESTING MARKET, 2024–2031 40
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023–2025 41
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF CARDIAC MARKER TESTING MARKET 42
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CARDIAC MARKER TESTING MARKET, 2025 43
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44
FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 45
FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 45
FIGURE 10 IMMUNOASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 46
FIGURE 11 MYOCARDIAL INFARCTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 46
FIGURE 12 TROPONIN I & T SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47
FIGURE 13 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47
FIGURE 14 SINGLEPLEX ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 48
FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD 48
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49
FIGURE 17 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
FIGURE 18 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 59
FIGURE 19 CARDIAC MARKER TESTING MARKET: SUPPLY CHAIN ANALYSIS 65
FIGURE 20 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 66
FIGURE 21 CARDIAC MARKER TESTING MARKET: ECOSYSTEM ANALYSIS 67
FIGURE 22 CARDIAC MARKER TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
FIGURE 23 NUMBER OF DEALS & FUNDING ACTIVITIES IN CARDIAC MARKER TESTING MARKET 73
FIGURE 24 PATENT ANALYSIS FOR CARDIAC MARKER TESTING,
JANUARY 2016–DECEMBER 2025 82
FIGURE 25 MARKET POTENTIAL OF AI IN CARDIAC MARKER TESTING MARKET 85
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 91
FIGURE 27 KEY BUYING CRITERIA, BY END USER 92
FIGURE 28 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 199
FIGURE 29 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 239
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023–2025 (USD MILLION) 287
FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL) 288
FIGURE 32 US: CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025 290
FIGURE 33 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 291
FIGURE 34 CARDIAC MARKER TESTING MARKET: COMPANY FOOTPRINT 292
FIGURE 35 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 295
FIGURE 36 EV/EBITDA OF KEY VENDORS 297
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 298
FIGURE 38 CARDIAC MARKER TESTING MARKET: BRAND/PRODUCT COMPARISON FOR CARDIAC MARKER TESTING 299
FIGURE 39 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 303
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2025) 308
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 311
FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 314
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025) 318
FIGURE 44 BIO-RAD LABORATORIES : COMPANY SNAPSHOT (2025) 321
FIGURE 45 BIOMÉRIEUX SA : COMPANY SNAPSHOT (2025) 323
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 326
FIGURE 47 DIASORIN SPA: COMPANY SNAPSHOT (2024) 328
FIGURE 48 REVVITY: COMPANY SNAPSHOT (2025) 330
FIGURE 49 TOSOH CORPORATION: COMPANY SNAPSHOT (2025) 333
FIGURE 50 QUIDEL CORPORATION: COMPANY SNAPSHOT (2025) 336
FIGURE 51 RESEARCH DESIGN 351
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 357
FIGURE 53 TOP-DOWN APPROACH 359
FIGURE 54 DATA TRIANGULATION 360
FIGURE 55 PARAMETRIC ASSUMPTIONS 362

---

---